Xenon Pharmaceuticals XENE Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's operating lease liabilities (current)?
- Xenon Pharmaceuticals (XENE) reported operating lease liabilities (current) of $1.56M in Q1 2026.
- How has Xenon Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Xenon Pharmaceuticals's operating lease liabilities (current) increased by 13.0% year-over-year, from $1.38M to $1.56M.
- What is the long-term trend for Xenon Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's operating lease liabilities (current) has grown at a 42.0% compound annual growth rate (CAGR), from $265K to $1.53M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.